Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.

Article  CAS  PubMed  Google Scholar 

MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–60.

Article  CAS  PubMed  Google Scholar 

Gérard J-P, André T, Bibeau F, et al. Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 2017;49:359–67.

Article  PubMed  Google Scholar 

Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.

Article  CAS  PubMed  Google Scholar 

Bosset JF, Calais G, Daban A, et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Eur J Cancer. 2004;40:219–24.

Article  CAS  PubMed  Google Scholar 

Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42.

Article  CAS  PubMed  Google Scholar 

Conroy T, Bosset J-F, Etienne P-L, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–15.

Article  CAS  PubMed  Google Scholar 

Paun BC, Cassie S, MacLean AR, et al. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010;251:807–18.

Article  PubMed  Google Scholar 

Peeters KCMJ. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199–206.

Article  CAS  PubMed  Google Scholar 

Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy. Trans Meeting Am Surg Assocs. 2004;CXXII:309–16.

Google Scholar 

Rullier E, Perez RO. Surgery or a watch-and-wait approach for rectal cancer? Lancet Oncol. 2019;20:189–90.

Article  PubMed  Google Scholar 

Gani C, Bonomo P, Zwirner K, et al. Organ preservation in rectal cancer – challenges and future strategies. Clin Transl Radiat Oncol. 2017;3:9–15.

CAS  PubMed  PubMed Central  Google Scholar 

Glynne-Jones R, Hughes R. Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg. 2012;99:897–909.

Article  CAS  PubMed  Google Scholar 

Arezzo A, Lo Secco G, Passera R, et al. Individual participant data pooled-analysis of risk factors for recurrence after neoadjuvant radiotherapy and transanal local excision of rectal cancer: the PARTTLE study. Tech Coloproctol. 2019;23:831–42.

Article  CAS  PubMed  Google Scholar 

Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88:822–8.

Article  PubMed  Google Scholar 

Fernandez LM, São Julião GP, Renehan AG, et al. The Risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the International Watch and Wait Database. Dis Colon Rectum. 2023;66:41–9.

Article  PubMed  Google Scholar 

Rullier E, Rouanet P, Tuech J-J, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017;390:469–79.

Article  PubMed  Google Scholar 

•• Rullier E, Vendrely V, Asselineau J, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5(5):465–474. https://doi.org/10.1016/S2468-1253(19)30410-8. The only prospective randomized trial comparing TME and rectal preservation in good responders after chemoradiation for T2/3 rectal cancers.

Larue RTHM, Defraene G, De Ruysscher D, et al. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. BJR. 2017;90:20160665.

Article  PubMed  PubMed Central  Google Scholar 

Kourou K, Exarchos TP, Exarchos KP, et al. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17.

Article  CAS  PubMed  Google Scholar 

Montagnon E, Cerny M, Cadrin-Chênevert A, et al. Deep learning workflow in radiology: a primer. Insights Imaging. 2020;11:22.

Article  PubMed  PubMed Central  Google Scholar 

Horvat N, Bates DDB, Petkovska I. Novel imaging techniques of rectal cancer: what do radiomics and radiogenomics have to offer? A literature review Abdom Radiol. 2019;44:3764–74.

Article  Google Scholar 

Cui Y, Liu H, Ren J, et al. Development and validation of a MRI-based radiomics signature for prediction of KRAS mutation in rectal cancer. Eur Radiol. 2020;30(4):1948-1958. https://doi.org/10.1007/s00330-019-06572-3.

Qin Y, Zhu L-H, Zhao W, et al. Review of radiomics- and dosiomics-based predicting models for rectal cancer. Front Oncol. 2022;12:913683.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen L-D, Li W, Xian M-F, et al. Preoperative prediction of tumour deposits in rectal cancer by an artificial neural network–based US radiomics model. Eur Radiol 2019

Cui Y, Yang X, Shi Z, et al. Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol. 2019;29:1211–20.

Article  PubMed  Google Scholar 

Bibault JE, Giraud P, Housset M, et al. Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer.  Sci Rep. 2018;8(1):12611. https://doi.org/10.1038/s41598-018-30657-6

Jeon SH, Song C, Chie EK, et al. Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy and surgery in rectal cancer. Radiat Oncol. 2019;14:43.

Article  PubMed  PubMed Central  Google Scholar 

De Cecco CN, Ganeshan B, Ciolina M, et al. Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance. Investig Radiol. 2015;50:239–45.

Article  Google Scholar 

Boldrini L, Cusumano D, Chiloiro G, et al. Delta radiomics for rectal cancer response prediction with hybrid 035 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach. Radiol med. 2019;124:145–53.

Article  PubMed  Google Scholar 

Lovinfosse P, Polus M, Van Daele D, et al. FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer. Eur J Nucl Med Mol Imaging. 2018;45:365–75.

Article  PubMed  Google Scholar 

Liu Z, Zhang X-Y, Shi Y-J, et al. Radiomics Analysis for evaluation of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Clin Cancer Res. 2017;23:7253–62. First large-scale study assessing the interest of radiomics analysis for neoadjuvant radiochemotherapy treatment response evaluation in rectal cancer.

Gourtsoyianni S, Doumou G, Prezzi D, et al. Primary Rectal cancer: repeatability of global and local-regional MR imaging texture features. Radiology. 2017;284:552–61.

Article  PubMed  Google Scholar 

Hu P, Wang J, Zhong H, et al. Reproducibility with repeat CT in radiomics study for rectal cancer. Oncotarget 2016 ; 7

Traverso A, Kazmierski M, Shi Z, et al. Stability of radiomic features of apparent diffusion coefficient (ADC) maps for locally advanced rectal cancer in response to image pre-processing. Physica Med. 2019;61:44–51.

Article  Google Scholar 

Chartrand G, Cheng PM, Vorontsov E, et al. Deep learning: a primer for radiologists. Radiographics. 2017;37:2113–31.

Article  PubMed  Google Scholar 

Lohmann P, Bousabarah K, Hoevels M, et al. Radiomics in radiation oncology-basics, methods, and limitations. Strahlenther Onkol. 2020;196:848–55.

Article  PubMed  PubMed Central  Google Scholar 

Bibault J-E, Xing L, Giraud P, et al. Radiomics: a primer for the radiation oncologist. Cancer Radiother. 2020;24:403–10.

Article  PubMed  Google Scholar 

Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62.

Article  PubMed  Google Scholar 

Stojanovic-Rundic S, Jankovic R, Micev M, et al. p21 does, but p53 does not predict pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. J Buon. 2017;22:1463–70.

PubMed  Google Scholar 

Saw RPM, Morgan M, Koorey D, et al. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum. 2003;46:192–202.

Article  PubMed  Google Scholar 

Chen M-B, Wu X-Y, Yu R, et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS One 2012; 7.

Sclafani F, Wilson SH, Cunningham D, et al. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. Int J Cancer. 2020;146:94–102.

Article  CAS  PubMed  Google Scholar 

Chow OS, Kuk D, Keskin M, et al. KRAS and combined KRAS/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy. Ann Surg Oncol. 2016;23:2548–55.

Article  PubMed  PubMed Central